

Apatorsen sodium

Cat. No.:	HY-145722
CAS No.:	915443-09-3
Molecular Weight:	7557
Sequence:	DNA, d(P-thio)([2'-O-(2-methoxyethyl)]rG-[2'-O-(2-methoxyethyl)]rG-[2'-O-(2-methoxyethyl)]rG-[2'-O-(2-methoxyethyl)]rA-m5C-G-m5C-G-G-m5C-G-m5C-T-m5C-G-G-[2'-O-(2-methoxyethyl)]m5rU-[2'-O-(2-methoxyethyl)]m5rC-[2'-O-(2-methoxyethyl)]rA-[2'-O-(2-methoxyethyl)]m5rU), nonadecasodium salt
Target:	HSP
Pathway:	Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Apatorsen (sodium)

BIOLOGICAL ACTIVITY

Description	Apatorsen (sodium) is an antisense oligonucleotide designed to bind to Hsp27 mRNA, resulting in the inhibition of the production of Hsp27 protein.
-------------	--

REFERENCES

- [1]. Yu EY, Ellard SL, Hotte SJ, et al. A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer. *Invest New Drugs*. 2018;36(2):278-287.
- [2]. Spigel DR, Shipley DL, Waterhouse DM, et al. A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial. *Oncologist*. 2019;24(12):e1409-e1416.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA